Cargando…

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune sys...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Liya, Kim, Hye-Jung, Wang, Qiwei, Kearns, Michael, Jiang, Tao, Ohlson, Carolynn E., Li, Ben B., Xie, Shaozhen, Liu, Joyce F., Stover, Elizabeth H., Howitt, Brooke E., Bronson, Roderick T., Lazo, Suzan, Roberts, Thomas M., Freeman, Gordon J., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Zhao, Jean J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366450/ https://www.ncbi.nlm.nih.gov/pubmed/30540933 http://dx.doi.org/10.1016/j.celrep.2018.11.054

Ejemplares similares

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
por: Wang, Qiwei, et al.
Publicado: (2022)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
por: Strickland, Kyle C., et al.
Publicado: (2016)

Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer
por: Rafii, Saeed, et al.
Publicado: (2017)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer
por: Pantelidou, Constantia, et al.
Publicado: (2022)

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2018)

An mRNA vaccine elicits STING-dependent antitumor immune responses
por: Chen, Zhe, et al.
Publicado: (2023)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
por: Przybytkowski, Ewa, et al.
Publicado: (2020)

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
por: Bustos, Matias A., et al.
Publicado: (2023)

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure
por: Lee, Elizabeth K., et al.
Publicado: (2019)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations
por: Shukla, Sachet A., et al.
Publicado: (2016)

PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
por: Lee, Elizabeth K., et al.
Publicado: (2020)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
por: Birkbak, Nicolai Juul, et al.
Publicado: (2013)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Parp1 protects against Aag-dependent alkylation-induced nephrotoxicity in a sex-dependent manner
por: Calvo, Jennifer A., et al.
Publicado: (2016)

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

PARP-1 Expression and BRCA1 Mutations in Breast Cancer Patients’ CTCs
por: Sklias, Thodoris, et al.
Publicado: (2022)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
por: Färkkilä, Anniina, et al.
Publicado: (2020)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
por: Hirotsu, Yosuke, et al.
Publicado: (2020)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials
por: Li, Shan, et al.
Publicado: (2021)

Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers
por: An, Liwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kn589kevs720otakn1s7lv1nhr